The Asthma & COPD Therapies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Expansion into Emerging Markets to Offer Lucrative Growth Opportunities
For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.
Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.
What Questions Should You Ask before Buying a Market Research Report?
• How is the asthma & COPD therapies market evolving?
• What is driving and restraining the asthma & COPD therapies market?
• How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the asthma & COPD therapies projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
asthma & COPD therapies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
• Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:
• Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Product
• Anti-inflammatory Drugs
• Bronchodilators Monotherapy
• Combination Drugs
Route of Administration
• Oral
• Inhaled
• Others
Point of Sale
• Retail Pharmacies
• Hospital Pharmacies
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.
• GSK plc
• Mundipharma
• Novartis AG
• Pulmatrix
• Respiratorius AB
• Sanofi SA
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• TFF Pharmaceuticals, Inc.
• Transpire Bio
• Verona Pharma plc
• Viatris Inc.
Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?
In summary, our 240+ page report provides you with the following knowledge:
• Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Asthma & COPD Therapies Market Report 2023-2033: Forecasts by Product (Anti-inflammatory Drugs, Bronchodilators Monotherapy, Combination Drugs), by Route of Administration (Oral, Inhaled, Others), by Point of Sale (Retail Pharmacies, Hospital Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Asthma & COPD Therapies Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Introduction to the COPD and Asthma Therapies Market
3.1 Introduction to the COPD and Asthma Therapies
3.2 The Pharmaceutical Industry: A Very Brief Overview
3.3 What is Asthma?
3.3.1 Trends in Asthma Prevalence
3.3.2 Pathophysiology of Asthma
3.3.3 Symptoms of Asthma
3.3.4 Causes and Triggers for Asthma
3.3.5 Treatment of Asthma
3.3.6 Drug Delivery Methods in Asthma
3.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
3.4.1 Trends in COPD Prevalence
3.4.2 Pathophysiology of COPD
3.4.3 Signs and Symptoms of COPD
3.4.4 Treatment of COPD
3.4.5 Drug Treatments for COPD
3.4.6 Guidelines for COPD Treatment
3.5 Major Drug Classes in the Treatment of Asthma and COPD
3.5.1 Bronchodilators
3.5.1.1 Beta2-Agonists
3.5.1.2 Anticholinergics
3.5.2 Anti-Inflammatory Drugs
3.5.2.1 Corticosteroids
3.5.2.2 Leukotriene Receptor Antagonists
3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
3.5.3 Combination Drugs
4 Market Overview
4.1 Key Findings
4.2 Market Dynamics
4.2.1 Market Driving Factors
4.2.2 Increasing Prevalence of Respiratory Diseases on Account of Increasing Pollution
4.2.3 Reducing Social Stigma Asthma and COPD
4.2.4 Strong Pipeline for Asthma Drugs
4.3 Market Restraints
4.4 Market Opportunities
4.4.1 Telehealth
4.5 Porter’s Five Forces
4.5.1 Bargaining Power of Buyers
4.5.2 Bargaining Power of Suppliers
4.5.3 Threat of Substitutes
4.5.4 Threat of New Entrants
4.5.5 Industry Rivalry
4.6 SWOT Analysis
4.7 COVID-19 Impact Analysis
5 Asthma & COPD Therapies Market Analysis by Product
5.1 Key Findings
5.2 Product Segment: Market Attractiveness Index
5.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Product
5.4 Anti-inflammatory Drugs
5.4.1 Anti-inflammatory Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)
5.5 Bronchodilators Monotherapy
5.5.1 Bronchodilators Monotherapy Submarket Forecast by Type, 2023-2033 (US$ bn)
5.6 Combination Drugs
5.6.1 Combination Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)
6 Asthma & COPD Therapies Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Route of Administration
6.4 Oral
6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Inhaled
6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Others
6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
7 Asthma & COPD Therapies Market Analysis by Point of Sale
7.1 Key Findings
7.2 Point of Sale Segment: Market Attractiveness Index
7.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Point of Sale
7.4 Retail Pharmacies
7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 Hospital Pharmacies
7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Others
7.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.6.2 Market Share by Region, 2023 & 2033 (%)
8 Asthma & COPD Therapies Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Asthma & COPD Therapies Market Analysis
9.1 Key Findings
9.2 North America Asthma & COPD Therapies Market Attractiveness Index
9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
9.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
9.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
9.7 U.S. Asthma & COPD Therapies Market Analysis
9.8 Canada Asthma & COPD Therapies Market Analysis
10 Europe Asthma & COPD Therapies Market Analysis
10.1 Key Findings
10.2 Europe Asthma & COPD Therapies Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
10.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
10.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
10.7 Germany Asthma & COPD Therapies Market Analysis
10.8 UK Asthma & COPD Therapies Market Analysis
10.9 France Asthma & COPD Therapies Market Analysis
10.10 Italy Asthma & COPD Therapies Market Analysis
10.11 Spain Asthma & COPD Therapies Market Analysis
10.12 Rest of Europe Asthma & COPD Therapies Market Analysis
11 Asia Pacific Asthma & COPD Therapies Market Analysis
11.1 Key Findings
11.2 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
11.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
11.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
11.7 Japan Asthma & COPD Therapies Market Analysis
11.8 China Asthma & COPD Therapies Market Analysis
11.9 India Asthma & COPD Therapies Market Analysis
11.10 Australia Asthma & COPD Therapies Market Analysis
11.11 South Korea Asthma & COPD Therapies Market Analysis
11.12 Rest of Asia Pacific Asthma & COPD Therapies Market Analysis
12 Latin America Asthma & COPD Therapies Market Analysis
12.1 Key Findings
12.2 Latin America Asthma & COPD Therapies Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
12.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
12.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
12.7 Brazil Asthma & COPD Therapies Market Analysis
12.8 Mexico Asthma & COPD Therapies Market Analysis
12.9 Rest of Latin America Asthma & COPD Therapies Market Analysis
13 MEA Asthma & COPD Therapies Market Analysis
13.1 Key Findings
13.2 MEA Asthma & COPD Therapies Market Attractiveness Index
13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
13.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
13.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
13.7 GCC Asthma & COPD Therapies Market Analysis
13.8 South Africa Asthma & COPD Therapies Market Analysis
13.9 Rest of MEA Asthma & COPD Therapies Market Analysis
14 Company Profiles
14.1 AstraZeneca
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2015-2021
14.1.3.2 Regional Market Shares, 2021
14.1.3.3 Gross Profit, 2015-2021
14.1.3.4 R&D, 2015-2021
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 GSK plc
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2015-2021
14.2.3.2 Regional Market Shares, 2021
14.2.3.3 Gross Profit, 2015-2021
14.2.3.4 R&D, 2015-2021
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Boehringer Ingelheim
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2021
14.3.3.2 Regional Market Shares, 2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Teva Pharmaceutical Industries Ltd.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2015-2021
14.4.3.2 Regional Market Shares, 2021
14.4.3.3 Gross Profit, 2015-2021
14.4.3.4 R&D, 2015-2021
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Viatris Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2015-2021
14.5.3.2 Gross Profit, 2015-2021
14.5.3.3 R&D, 2015-2021
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 F. Hoffmann-La Roche Ltd.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2021
14.6.3.2 Gross Profit, 2015-2021
14.6.3.3 R&D, 2015-2021
14.6.4 Product Benchmarking
14.7 Novartis AG
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2015-2021
14.7.3.2 Regional Market Shares, 2021
14.7.3.3 Gross Profit, 2015-2021
14.7.3.4 R&D, 2015-2021
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Mundipharma
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.9 Cipla Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2015-2021
14.9.3.2 Regional Market Shares, 2021
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Pulmatrix
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.10.4 Strategic Outlook
14.11 TFF Pharmaceuticals, Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.11.4 Strategic Outlook
14.12 Respiratorius AB
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.13 Chiesi Farmaceutici S.p.A.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Grifols S.A.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Net Revenue, 2015-2021
14.14.3.2 Regional Market Shares, 2021
14.14.3.3 Gross Profit, 2015-2021
14.14.3.4 R&D, 2015-2021
14.14.4 Product Benchmarking
14.14.5 Strategic Outlook
14.15 Sanofi SA
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 Regional Market Shares, 2021
14.15.3.3 Gross Profit, 2015-2021
14.15.3.4 R&D, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Sunovion Pharmaceuticals Inc.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.17 Transpire Bio
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.18 Verona Pharma plc
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Asthma & COPD Therapies Market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
Table 2 Key Factors Affecting the Bargaining Power of Buyer
Table 3 Key Factors Affecting the Bargaining Power of Suppliers
Table 4 Key Factors Affecting the Threat of Substitutes
Table 5 Key Factors Affecting the Threat of New Entrants
Table 6 Key Factors Affecting the Industry Rivalry
Table 7 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 8 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 9 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 10 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 11 Asthma & COPD Therapies Market Forecast by Product, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 12 Anti-inflammatory Drugs Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 13 Bronchodilators Monotherapy Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 14 Combination Drugs Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 15 Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 16 Oral Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 17 inhaled Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 18 Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 19 Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 20 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 22 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 23 North America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 24 North America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 25 North America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 26 U.S. Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 27 U.S. Asthma Prevalence, 2020
Table 28 Canada Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 29 Europe Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 30 Europe Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 31 Europe Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 32 Germany Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 33 UK Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 34 France Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 35 Italy Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 36 Spain Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 37 Rest of Europe Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 38 Asia Pacific Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 39 Asia Pacific Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 40 Asia Pacific Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 41 Japan Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 42 China Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 43 India Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 44 Australia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 45 South Korea Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 46 Rest of Asia Pacific Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 47 Latin America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 48 Latin America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 49 Latin America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 50 Brazil Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 51 Mexico Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 52 Rest of Latin America Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 53 MEA Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 54 MEA Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 55 MEA Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 56 GCC Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 57 South Africa Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 58 Rest of MEA Arabia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 59 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 AstraZeneca: Key Marketed Products
Table 61 AstraZeneca: Product Benchmarking
Table 62 AstraZeneca: Strategic Outlook
Table 63 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 GSK plc: Product Benchmarking
Table 65 GSK plc: Strategic Outlook
Table 66 Boehringer Ingelheim: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Boehringer Ingelheim: Product Benchmarking
Table 68 Boehringer Ingelheim: Strategic Outlook
Table 69 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 71 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 72 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Viatris Inc.: Product Benchmarking
Table 74 Viatris Inc.: Strategic Outlook
Table 75 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 77 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Novartis AG: Product Benchmarking
Table 79 Novartis AG: Strategic Outlook
Table 80 Mundipharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Mundipharma: Product Benchmarking
Table 82 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Cipla Inc.: Product Benchmarking
Table 84 Cipla Inc.: Strategic Outlook
Table 85 Pulmatrix: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Pulmatrix: Product Benchmarking
Table 87 Pulmatrix: Strategic Outlook
Table 88 TFF Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 TFF Pharmaceuticals, Inc.: Product Benchmarking
Table 90 TFF Pharmaceuticals, Inc.: Strategic Outlook
Table 91 Respiratorius AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Respiratorius AB: Product Benchmarking
Table 93 Chiesi Farmaceutici S.p.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Chiesi Farmaceutici S.p.A.: Product Benchmarking
Table 95 Grifols S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Grifols S.A.: Product Benchmarking
Table 97 Grifols S.A.: Strategic Outlook
Table 98 Sanofi SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Sanofi SA: Product Benchmarking
Table 100 Sanofi SA: Strategic Outlook
Table 101 Sunovion Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Sunovion Pharmaceuticals Inc.: Product Benchmarking
Table 103 Transpire Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Transpire Bio: Product Benchmarking
Table 105 Verona Pharma plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Verona Pharma plc: Product Benchmarking
Table 107 Verona Pharma plc: Strategic Outlook
List of Figures
Figure 1 Asthma & COPD Therapies Market Segmentation
Figure 2 Asthma & COPD Therapies Market by Product: Market Attractiveness Index
Figure 3 Asthma & COPD Therapies Market by Route of Administration: Market Attractiveness Index
Figure 4 Asthma & COPD Therapies Market by Point of Sale: Market Attractiveness Index
Figure 5 Asthma & COPD Therapies Market Attractiveness Index by Region
Figure 6 Asthma & COPD Therapies Market: Market Dynamics
Figure 7 Porter’s Five Forces
Figure 8 SWOT Analysis
Figure 9 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): “V” Shaped Recovery
Figure 10 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): “U” Shaped Recovery
Figure 11 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): “W” Shaped Recovery
Figure 12 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): “L” Shaped Recovery
Figure 13 Asthma & COPD Therapies Market Attractiveness Index by Product
Figure 14 Asthma & COPD Therapies Market Forecast by Product, 2023-2033 (US$ billion)
Figure 15 Asthma & COPD Therapies Market Share Forecast by Product, 2023, 2028, 2033 (%)
Figure 16 Asthma & COPD Therapies Market Attractiveness Index by Product
Figure 17 Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 18 Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
Figure 19 Oral Market Forecast by Region, 2023-2033 (US$ billion)
Figure 20 Oral Market Share Forecast by Region, 2023 & 2033 (%)
Figure 21 Inhaled Market Forecast by Region, 2023-2033 (US$ billion)
Figure 22 Inhaled Market Share Forecast by Region, 2023 & 2033 (%)
Figure 23 Others Market Forecast by Region, 2023-2033 (US$ billion)
Figure 24 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 25 Asthma & COPD Therapies Market Attractiveness Index by Point of Sale
Figure 26 Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 27 Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023, 2028, 2033 (%)
Figure 28 Retail Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
Figure 29 Retail Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
Figure 31 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Others Market Forecast by Region, 2023-2033 (US$ billion)
Figure 33 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Asthma & COPD Therapies Market Forecast by Region 2023-2033 (Revenue, CAGR%)
Figure 35 Asthma & COPD Therapies Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 36 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ bn)
Figure 37 North America Asthma & COPD Therapies Market Attractiveness Index
Figure 38 North America Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 39 North America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
Figure 40 North America Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
Figure 41 North America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 42 North America Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 43 North America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 44 North America Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
Figure 45 U.S. Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 46 Canada Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 47 Europe Asthma & COPD Therapies Market Attractiveness Index
Figure 48 Europe Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 49 Europe Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
Figure 50 Europe Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
Figure 51 Europe Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 52 Europe Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 53 Europe Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 54 Europe Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
Figure 55 Germany Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 56 UK Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 57 France Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 58 Italy Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 59 Spain Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 60 Rest of Europe Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 61 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
Figure 62 Asia Pacific Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 63 Asia Pacific Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
Figure 64 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
Figure 65 Asia Pacific Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 66 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 67 Asia Pacific Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 68 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
Figure 69 Japan Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 70 China Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 71 India Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 72 Australia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 73 South Korea Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 74 Rest of Asia Pacific Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 75 Latin America Asthma & COPD Therapies Market Attractiveness Index
Figure 76 Latin America Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 77 Latin America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
Figure 78 Latin America Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
Figure 79 Latin America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 80 Latin America Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 81 Latin America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 82 Latin America Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
Figure 83 Brazil Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 84 Mexico Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 85 Rest of Latin America Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 86 MEA Asthma & COPD Therapies Market Attractiveness Index
Figure 87 MEA Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 88 MEA Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
Figure 89 MEA Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
Figure 90 MEA Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
Figure 91 MEA Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 92 MEA Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
Figure 93 MEA Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
Figure 94 GCC Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 95 South Africa Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 96 Rest of MEA Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 97 AstraZeneca: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 98 AstraZeneca: Regional Market Shares (%), 2021
Figure 99 AstraZeneca: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 100 AstraZeneca: R&D, 2015-2021 (US$ million, AGR%)
Figure 101 GSK plc: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 102 GSK plc: Regional Market Shares (%), 2021
Figure 103 GSK plc: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 104 GSK plc: R&D, 2015-2021 (US$ million, AGR%)
Figure 105 Boehringer Ingelheim: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 106 Boehringer Ingelheim: Regional Market Shares (%), 2021
Figure 107 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 108 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2021
Figure 109 Teva Pharmaceutical Industries Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 110 Teva Pharmaceutical Industries Ltd.: R&D, 2015-2021 (US$ million, AGR%)
Figure 111 Viatris Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 112 Viatris Inc.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 113 Viatris Inc.: R&D, 2015-2021 (US$ million, AGR%)
Figure 114 F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 115 F. Hoffmann-La Roche Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 116 F. Hoffmann-La Roche Ltd.: R&D, 2015-2021 (US$ million, AGR%)
Figure 117 Novartis AG: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 118 Novartis AG: Regional Market Shares (%), 2021
Figure 119 Novartis AG: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 120 Novartis AG: R&D, 2015-2021 (US$ million, AGR%)
Figure 121 Cipla Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 122 Cipla Inc.: Regional Market Shares (%), 2021
Figure 123 Grifols S.A.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 124 Grifols S.A.: Regional Market Shares (%), 2021
Figure 125 Grifols S.A.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 126 Grifols S.A.: R&D, 2015-2021 (US$ million, AGR%)
Figure 127 Sanofi SA: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 128 Sanofi SA: Regional Market Shares (%), 2021
Figure 129 Sanofi SA: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 130 Sanofi SA: R&D, 2015-2021 (US$ million, AGR%)
List of Companies Profiled in the Report
AstraZeneca
Boehringer Ingelheim
Chiesi Farmaceutici S.p.A.
Cipla Inc.
F. Hoffmann-La Roche Ltd.
Grifols S.A.
GSK plc
Mundipharma
Novartis AG
Pulmatrix
Respiratorius AB
Sanofi SA
Sunovion Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
TFF Pharmaceuticals, Inc.
Transpire Bio
Verona Pharma plc
Viatris Inc.
List of Other Companies Mentioned in the Report
3P innovation Ltd
Ab Initio Pharma Ltd
Berry Global Inc.
Briggs of Burton Plc
Catalent, Inc.
CD Bioparticles
Celanese
CF PharmTech, Inc.
Copley Scientific Limited
Coster Tecnologie Speciali S.p.A
DFE Pharma
DH Industries Limited
ELIX Polymers
Fluidda
Gerresheimer Medical Systems
H&T Presspart
HCmed Innovations Co., Ltd.
Hosokawa Micron Powder Systems
Hovione
Iconovo
Inhalation Sciences
Jabil Inc.
Kenox Pharmaceuticals, Inc.
Kindeva Drug Delivery
Lab Automate Technologies Inc
MEGGLE Group GmbH
MG America (U.S.)
Micro-Sphere S.A.
Nemera
PARI GmbH
Teleflex Incorporated
Wellbridge Biological Technology
List of Associations Mentioned in the Report
ACRF Centre for Advanced Respiratory Drug Delivery Technologies
Agencia Nacional de Vigiloncia Sanitaria (ANVISA)
American Cancer Society (ACS)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Center of Excellence in Cystic Fibrosis (CEI)
Centers for Disease Control and Prevention (CDC)
Centers for Medicare & Medicaid Services programs
European Medicines Agency (EMA)
European Union
Food and Drug Administration (FDA)
Government of Japan
Health Ministry (Italy)
Indian Council of Medical Research (ICMR)
Institute for Healthcare Improvement (IHI)
International Agency for Research on Cancer (IARC)
Italian Industry Group Farmindustria
Japanese Ministry of Health, Labour and Welfare
Laboratory of Tumor Cystic Fibrosis and Biology at CCR
Medicines and Healthcare Products Regulatory Agency (MHRA)
Ministry of Health, Labour & Welfare (MHLW)
National Cancer Institute (NCI)
National Cancer Institute's Center for Cancer Research (CCR)
National Development and Reform Commission (NDRC)
National Institutes of Health (NIH)
NCBI
The Therapeutic Goods Administration
United Nations (UN)
University of Connecticut
World Health Organization (WHO)
World Population Prospects
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
